ESR1 and breast cancer: Breast cancer is a heterogeneous disease with diverse pathological features and survival outcomes (Sorlie et al., 2003), and the basal-like or triple-negative BRCAs (TNBCs, lacking expression of the ER, PR and HER2), characterized by a poor prognosis and no specific targeted therapies group (Badve et al., 2011).